Compare Stocks → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS). Comparison Ideas Agriculture StocksAirline StocksApparel StocksArtificial Intelligence StocksAutomotive StocksBank StocksBitcoin StocksBlockchain StocksCanadian StocksCannabis StocksCasino StocksChatGPT StocksChinese StocksCloud Storage StocksCoronavirus Therapeutics StocksCryptocurrency StocksCybersecurity StocksDefense StocksDividend StocksDow 30 StocksEcommerce StocksElectric Vehicles StocksEnergy StocksEntertainment StockseSports StocksEV Charging StocksFertilizer StocksGold StocksGrocery StocksGrowth StocksHealthcare StocksHigh Dividend StocksHome Office StocksHotel StocksLarge Cap StocksLeisure StocksLithium StocksMagnificent Seven StocksMATANA StocksMega Cap StocksMeme StocksMetaverse StocksMid Cap StocksMining StocksMusic Industry StocksNanotechnology StocksNFT StocksOil StocksOutdoor Activities StocksPharmaceutical StocksRenewable Energy StocksRestaurant StocksRetail StocksSemiconductor StocksSocial Media StocksSolar StocksSpace StocksStay-At-Home StocksTechnology StocksTelecom StocksToy StocksUtility StocksVaccine StocksVideo Game StocksVirtual Reality StocksWallStreetBets Stocks Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare Share Comparison Share Comparison NYSEARCA:AORNASDAQ:SBTX Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Stocks - Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAORiShares Core Growth Allocation ETF$53.97-0.2%$54.64$47.56▼$55.74$1.99B0.62261,618 shs352,637 shsSBTXSilverback Therapeutics$8.50+3.5%$8.77$2.80▼$8.97$306.49M0.6337,931 shs510,339 shsThe Best High-Yield Dividend Stocks for 2024Looking to generate income with your stock portfolio? Use these ten stocks to generate a safe and reliable source of investment income.Get This Free ReportPrice PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAORiShares Core Growth Allocation ETF+0.82%+0.88%-2.49%+2.10%+7.53%SBTXSilverback Therapeutics0.00%-10.57%-5.09%+28.68%+25.73%Exposed: 10 CENT Crypto to Explode April 20th? (Ad)Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAORiShares Core Growth Allocation ETFN/AN/AN/AN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/AN/AN/AN/AAnalyst RatingsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAORiShares Core Growth Allocation ETF0.00N/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/ASales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAORiShares Core Growth Allocation ETFN/AN/AN/AN/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/A$7.41 per shareN/AProfitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAORiShares Core Growth Allocation ETFN/AN/A17.21∞N/AN/AN/AN/AN/ASBTXSilverback Therapeutics-$89.48M-$2.42N/A∞N/AN/A-29.62%-28.20%N/ADividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAORiShares Core Growth Allocation ETF$1.082.00%N/AN/AN/ASBTXSilverback TherapeuticsN/AN/AN/AN/AN/ADebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAORiShares Core Growth Allocation ETFN/AN/AN/ASBTXSilverback TherapeuticsN/A67.8767.87OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAORiShares Core Growth Allocation ETFN/ASBTXSilverback Therapeutics74.89%Insider OwnershipCompanyInsider OwnershipAORiShares Core Growth Allocation ETFN/ASBTXSilverback Therapeutics34.40%MiscellaneousCompanyEmployeesShares OutstandingFree FloatOptionableAORiShares Core Growth Allocation ETFN/A36.80 millionN/ANot OptionableSBTXSilverback Therapeutics8336.06 million23.65 millionNot OptionableC4XD, BXN, SBTX, AOR, and RLM HeadlinesSourceHeadlineSilverback Therapeutics (NASDAQ:SBTX) Trading Down 2%marketbeat.com - April 3 at 2:15 AMARS Pharmaceuticals Inc (SPRY)uk.investing.com - May 11 at 1:32 PMWild Isleswwf.org.uk - March 12 at 9:31 AMA look back at RNA Therapeutics – day onepharmaphorum.com - February 24 at 12:35 AMSPRY ARS Pharmaceuticals, Inc.seekingalpha.com - January 24 at 8:04 PMARS Pharma CEO Richard Lowenthal Holds 8% Silverback Stake After Merger247wallst.com - November 22 at 6:29 AMDr. Sarina Tanimoto Discloses Position in SBTX / Silverback Therapeuticsnasdaq.com - November 18 at 8:19 PMARS Pharmaceuticals Announces Presentation of Clinical Data Supporting neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (Type I) including Anaphylaxisfinance.yahoo.com - November 10 at 6:41 PMARS Pharmaceuticals Closes Merger with Silverback Therapeuticsfinance.yahoo.com - November 8 at 5:59 PMSilverback : FDA Accepts ARS Pharm's NDA For Neffy For Treatment Of Allergic Reactionsmarkets.businessinsider.com - October 28 at 8:15 AMFDA accepts ARS Pharma’s NDA for Neffythepharmaletter.com - October 24 at 10:29 AMSHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates HIL, SBTX, COWN, AERIkentuckytoday.com - October 23 at 7:22 PMSilverback Therapeutics, Inc. announces the FDA’s acceptance of ARS Pharmaceuticals’ NDA for neffy® (epinephrine nasal spray) for the Treatment of Allergic Reactions (type I) including Anaphylaxisfinance.yahoo.com - October 21 at 7:59 AMIs Silverback Therapeutics Inc (SBTX) Stock a Good Investment?aaii.com - October 19 at 11:52 AMSHAREHOLDER ALERT: The M&A Class Action Firm is Investigating the Merger – RFP, SBTX, AAWW, COWNbakersfield.com - October 12 at 11:07 PMINVESTIGATION ALERT: Halper Sadeh LLC Investigates CVET, SBTX, IRBTmarkets.businessinsider.com - September 17 at 5:10 AMSBTX Silverback Therapeutics, Inc.seekingalpha.com - September 15 at 10:58 PMSHAREHOLDER NOTICE: Halper Sadeh LLP Investigates FTAI, SBTX, CVET, GBTmarkets.businessinsider.com - September 6 at 11:53 AMSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZYmarkets.businessinsider.com - August 23 at 6:32 PMSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates VIVO, HNGR, SBTXapnews.com - August 17 at 12:02 PMSHAREHOLDER INVESTIGATION NOTICE: Halper Sadeh LLP Investigates IEA, BBQ, SBTXapnews.com - August 11 at 1:33 AMSHAREHOLDER ALERT: Weiss Law Reminds SBTX, LJPC, CNVY, and DRE Shareholders About Its Ongoing Investigationsmorningstar.com - July 30 at 7:00 AMINVESTIGATION ALERT: Halper Sadeh LLP Investigates HNGR, SBTX, IEA, ZYapnews.com - July 28 at 2:21 AMShareholder Alert - The M&A Class Action Firm Announces the Investigation of Silverback Therapeutics, Inc. - SBTXbenzinga.com - July 27 at 9:21 PMNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCompany DescriptionsiShares Core Growth Allocation ETFNYSEARCA:AORiShares Growth Allocation ETF, formerly iShares S&P Growth Allocation Fund (the Fund), is an open-end management investment company. The Fund seeks investment results that correspond generally to the price and yield performance of the S&P Target Risk Growth Index (the Growth Allocation Index). The Growth Allocation Index seeks to measure the performance of an asset allocation strategy targeted to a growth-focused risk profile. The Fund is designed for investors seeking moderate capital appreciation and opportunity for current income and capital preservation. The Fund's investment advisor is BlackRock Fund Advisors.Silverback TherapeuticsNASDAQ:SBTXSilverback Therapeutics, Inc., a biopharmaceutical company, develops tissue-targeted therapeutics for the treatment of chronic viral infections, cancer, and other serious diseases. The company offers SBT8230 to treat chronic hepatitis B virus infection by eliciting an anti-viral immune response by targeting TLR8 activation to the liver. Silverback Therapeutics, Inc. was incorporated in 2016 and is headquartered in Seattle, Washington. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.